SCYNEXIS Announces Acceptance of Abstracts Related to its Hepatitis C Clinical Candidate, SCY-635, for Presentation at 45th Annual Meeting of the European Association for the Study of the Liver
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Apr 5, 2010 - Drug discovery company, SCYNEXIS, Inc. today announced that multiple abstracts related to the Company's cyclophilin inhibitor, SCY-635, were accepted for presentation at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria, April 14-18, 2010. SCY-635, a cyclophilin inhibitor, represents a new class of drugs for the treatment of hepatitis C virus (HCV) infection and is the first candidate from a broad platform of proprietary cyclophilin inhibitors developed by SCYNEXIS. Full abstracts can be viewed at the EASL website at www.easl.eu.
SCY-635 Oral Presentation
“Resistance Selection Following 15 Days of Monotherapy with SCY-635 a Non-immunosuppressive Cyclophilin Inhibitor with Potent Anti-HCV Activity,” Thursday, April 15, 2010, 17:45 to 18:00 CET.
SCY-635 Poster Presentations
“The Effects of SCY-635 a Non-immunosuppressive Cyclosporin Analog on Stellate Cell Proliferation, Collagen Synthesis, TIMP-1 and Collagenase Production,” Friday, April 16, 2010
“In vitro Models for Assessing the Relative Risk of Hyperbilirubinemia Associated with Cyclophilin Inhibitor Therapy,” Friday, April 16, 2010
About SCY-635 and SCYNEXIS' Cyclophilin Inhibitor Platform
SCY-635 represents a new class of therapeutic agents for the treatment of HCV infection. SCY-635 is the first candidate in a novel class of non-immunosuppressive cyclophilin inhibitors owned by SCYNEXIS. Cyclophilins are a family of enzymatic proteins that assist in the folding and transport of other proteins synthesized within a cell. Scientists at SCYNEXIS have synthesized derivatives of Cyclosporine A in which cyclophilin binding activity (which mediates anti-HCV activity) is separated from calcineurin binding activity (which mediates immunosuppression). A growing body of scientific evidence indicates that non-immunosuppressive analogs of Cyclosporine A may have applications in multiple therapeutic areas. Cyclophilins play a central role in the pathophysiology of chronic viral infection, neuro- and cardio- degenerative diseases. Cyclophilin inhibition therefore represents an attractive target for drug discovery and development.
SCYNEXIS is a premier drug discovery and development company delivering effective and innovative drug pipeline solutions to pharmaceutical and global health partners. Our record of success is demonstrated by the delivery of 11 pre-clinical and clinical drug candidates over the last 5 years. The Company, which is located in Research Triangle Park, North Carolina, is developing a proprietary internal pipeline based on cyclophilin inhibitors, a class of drugs that hold significant potential for the treatment of a broad range of diseases. Please visit our website at www.scynexis.com.
Contact: MacDougall Biomedical Communications
Sarah Cavanaugh, 781-235-3060
Terry Marquardt, 919-544-8603
Posted: April 2010